Aviezer David 4
4 · Protalix BioTherapeutics, Inc. · Filed May 4, 2012
Insider Transaction Report
Form 4
Aviezer David
DirectorPresident & CEO
Transactions
- Sale
Common Stock
2012-05-02$7.13/sh−450,000$3,208,500→ 0 total(indirect: By Trust) - Exercise/Conversion
Common Stock
2012-05-02$0.97/sh+123,733$120,268→ 450,000 total(indirect: By Trust) - Exercise/Conversion
Common Stock
2012-05-02$0.12/sh+326,267$39,152→ 326,267 total(indirect: By Trust) - Exercise/Conversion
Stock Options (Right to Buy)
2012-05-02−326,267→ 0 totalExercise: $0.12Exp: 2013-12-08→ Common Stock (326,267 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2012-05-02−123,733→ 853,563 totalExercise: $0.97Exp: 2016-09-10→ Common Stock (123,733 underlying)
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
- [F3]All of the options listed in Table II have vested.
- [F4]Does not include (i) options to purchase 600,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018, (ii) options to purchase 100,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019, and (iii) options to purchase 250,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020.